证券代码：600488 证券简称：津药药业 编号：2025-063 津药药业股份有限公司 近日，津药药业股份有限公司（以下简称"公司"）控股子公司津 药和平（天津）制药有限公司（以下简称"津药和平"）、湖北津药药 业股份有限公司（以下简称"湖北津药"）参加了国家组织药品联合 采购办公室（以下简称"联采办"）组织的第十一批全国药品集中采 购，倍他米松磷酸钠注射液、盐酸溴己新注射液、盐酸甲氧氯普胺注 射液、二羟丙茶碱注射液、异烟肼注射液、盐酸肾上腺素注射液、法 莫替丁注射液七个产品拟中选本次集中采购。现将相关情况公告如 下： | 产品名称 | 适应症 | 规格 | 拟中选价格 | 拟供应省份 | 采购周期 | | --- | --- | --- | --- | --- | --- | | 倍他米松磷 | 主要用于过敏性与自身免疫性炎症 性疾病。现多用于活动性风湿病、类 风湿性关节炎、红斑狼疮、严重支气 | 1ml:4mg | 1.1 元/支 | 江苏、湖北、 山西、黑龙江、 | 自中选结果 执行之日起 年 | | 酸钠注射液 | 管哮喘、严重皮炎、急性白血病等， | | | 青海 | 至 2028 | | | | ...

Core Viewpoint - The company announced that its subsidiaries participated in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with seven products expected to be selected for this procurement [1] Group 1: Procurement Participation - The subsidiaries of the company, Tianjin Pharmaceutical Peace Pharmaceutical Co., Ltd. and Hubei Tianjin Pharmaceutical Co., Ltd., are involved in the national centralized drug procurement [1] - The seven products proposed for selection include Betamethasone Sodium Phosphate Injection, Ambroxol Hydrochloride Injection, Metoclopramide Hydrochloride Injection, Theophylline Injection, Isoniazid Injection, Adrenaline Hydrochloride Injection, and Famotidine Injection [1] Group 2: Financial Impact - The total projected sales revenue from the selected products for the year 2024 is approximately 95.16 million yuan, accounting for 2.96% of the company's total revenue for that year [1] - For the first three quarters of 2025, the projected sales revenue from these products is approximately 22.08 million yuan, representing 0.99% of the company's revenue for that period [1]

Core Insights - Tianjin Pharmaceutical Industry Co., Ltd. (600488.SH) reported a total operating revenue of 2.232 billion yuan for Q3 2025, ranking 28th among disclosed peers, which represents a decrease of 341 million yuan or 13.24% year-on-year [1] - The net profit attributable to shareholders was 69.54 million yuan, ranking 54th among peers, down by 117 million yuan or 62.75% compared to the same period last year [1] - The net cash flow from operating activities was 33.39 million yuan, ranking 65th among peers, a decrease of 421 million yuan or 92.65% year-on-year [1] Financial Ratios - The latest debt-to-asset ratio is 32.19%, ranking 51st among peers, down by 1.79 percentage points from the previous quarter and 3.42 percentage points from the same period last year [3] - The latest gross profit margin is 40.76%, ranking 52nd among peers, a decrease of 0.95 percentage points from the previous quarter and 3.67 percentage points year-on-year [3] - The latest return on equity (ROE) is 2.30%, ranking 61st among peers, down by 3.82 percentage points compared to the same period last year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share is 0.06 yuan, ranking 63rd among peers, a decrease of 0.11 yuan or 62.57% year-on-year [3] - The latest total asset turnover ratio is 0.39 times, ranking 24th among peers, a decrease of 0.03 times or 8.00% year-on-year [3] - The latest inventory turnover ratio is 2.07 times, ranking 35th among peers, an increase of 0.13 times or 6.94% year-on-year, marking two consecutive years of growth [3] Shareholder Information - The number of shareholders is 38,400, with the top ten shareholders holding 651 million shares, accounting for 59.64% of the total share capital [3] - The largest shareholder is Tianjin Pharmaceutical Group Co., Ltd., holding 507 million shares [3]

格隆汇10月28日丨津药药业(600488.SH)发布三季报，2025年前三季度实现营业总收入22.32亿元，同比 下降13.24%；归属母公司股东净利润6953.99万元，同比下降62.75%；基本每股收益为0.064元。 ...

信息披露暂缓与豁免管理制度 津药药业股份有限公司 信息披露暂缓与豁免管理制度 （2025年10月28日第九届董事会第二十一次会议审议通过） 第一章 总 则 第一条 为规范津药药业股份有限公司（以下简称"公 司"）信息披露暂缓、豁免行为，保障公司及相关信息披露 义务人依法合规履行信息披露义务，切实保护公司、股东、 债权人及其他利益相关者的合法权益，根据《中华人民共和 国证券法》《上市公司信息披露管理办法》《上海证券交易所 股票上市规则》《上市公司信息披露暂缓与豁免管理规定》 等有关法律、法规、规章以及《津药药业股份有限公司信息 披露事务管理制度》（以下简称"《信息披露事务管理制度》"） 等有关规定，结合公司实际情况，制定本制度。 第二条 公司和其他信息披露义务人暂缓、豁免披露临时 报告，在定期报告、临时报告中豁免披露中国证券监督管理 委员会（以下简称中国证监会）和上海证券交易所规定或者 要求披露的内容，适用本制度。 第三条 公司和其他信息披露义务人应当真实、准确、完 整、及时、公平地披露信息，不得滥用暂缓或者豁免披露规 避信息披露义务、误导投资者，不得实施内幕交易、操纵市 场等违法行为。 第二章 暂缓、豁免披露 ...

证券代码：600488 证券简称：津药药业 编号：2025-062 津药药业股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●会议召开时间：2025年11月19日(星期三)下午14:00-15:00 ●会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） ●会议召开方式：上证路演中心网络互动 1 / 3 二、说明会召开的时间、地点 ●投资者可于2025年11月12日(星期三) 至11月18日(星期 二)16:00前登录上证路演中心网站首页点击"提问预征集"栏目或通 过公司邮箱（tjpc600488@vip.sina.com）进行提问。公司将在说明 会上对投资者普遍关注的问题进行回答。 津药药业股份有限公司（以下简称"公司"）已于2025年10月29 日发布公司2025年第三季度报告，为便于广大投资者更全面深入地了 解公司2025年第三季度经营成果、财务状况，公司计划于2025年11 月1 ...

证券代码：600488 证券简称：津药药业 编号：2025-061 津药药业股份有限公司 关于计提减值准备及核销资产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 津药药业股份有限公司（以下简称"公司"）于2025年10月28 日召开公司第九届董事会第二十一次会议，审议通过了《关于计提减 值准备及核销资产的议案》。具体情况如下： 一、资产减值准备的计提概况 为了更加客观、公允地反映公司2025年9月30日的财务状况以及 2025年前三季度的经营成果，根据《企业会计准则》相关规定和公司 会计政策，基于谨慎性原则，公司对相关资产进行减值测试，本期计 提各项减值准备共计4,779.44万元，收回或转回387.08万元，转销 3,591.74万元。具体如下： 关会计政策，其他应收款按历史经验数据和前瞻性信息计提坏账准 备，经测试2025年前三季度计提坏账23.26万元，转回9.78万元。 3.存货跌价准备 二、资产减值准备计提具体情况说明 1.应收账款坏账准备 根据《企业会计准则第 22 号—金融工具确认和计量》以及公司 ...

证券代码：600488 证券简称：津药药业 编号：2025-060 津药药业股份有限公司 第九届董事会第二十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 表决结果：同意票 9 票，反对票 0 票，弃权票 0 票。 2.审议通过关于计提减值准备及核销资产的议案 公司依据实际情况计提减值准备及核销资产，符合《企业会计准 则》和公司财务管理制度的相关规定，公允地反映了公司的资产状况， 同意公司本次计提减值准备及核销资产的议案。具体内容详见上海证 券交易所网站（www.sse.com.cn）同日披露的公告。 表决结果：同意票 9 票，反对票 0 票，弃权票 0 票。 3.审议通过关于聘任公司首席人力资源官的议案 经总经理李书箱先生提名，公司薪酬与提名委员会审议通过，聘 任李中兴先生为公司首席人力资源官。李中兴先生简历如下： 1 李中兴，男，1979 年出生，天津师范大学全日制本科学历，天 津大学工程硕士。历任天津中新药业中新制药厂生产部外经主管、制 剂车间副主任，天津中新药业中新制药厂综合办公室主任、提取车间 ...

Financial Performance - Revenue for the third quarter was CNY 643,160,745.08, a decrease of 16.61% compared to the same period last year[5] - Total profit for the quarter was CNY 28,002,000.48, down 54.13% year-over-year[5] - Net profit attributable to shareholders was CNY 20,235,616.33, reflecting a decline of 54.70% compared to the previous year[5] - The basic earnings per share for the quarter was CNY 0.019, a decrease of 53.66% year-over-year[5] - Total operating revenue for the first three quarters of 2025 was approximately CNY 2.23 billion, a decrease of 13.2% compared to CNY 2.57 billion in the same period of 2024[19] - Net profit for the first three quarters of 2025 was approximately CNY 112.30 million, a decrease of 53.0% compared to CNY 238.87 million in the same period of 2024[20] - Basic and diluted earnings per share for the first three quarters of 2025 were CNY 0.064, down from CNY 0.171 in the same period of 2024[21] - The company reported a total comprehensive income of approximately CNY 113.41 million for the first three quarters of 2025, compared to CNY 241.62 million in the same period of 2024[21] Assets and Liabilities - Total assets at the end of the quarter were CNY 5,743,140,242.33, an increase of 0.79% from the end of the previous year[6] - Shareholders' equity attributable to the parent company was CNY 3,023,050,596.16, a decrease of 1.12% from the previous year[6] - The company's current assets totaled RMB 1,995,467,697.94, up from RMB 1,804,458,969.26, indicating an increase of about 10.59% year-over-year[15] - The accounts receivable increased significantly to RMB 566,125,096.12 from RMB 291,238,382.36, representing a growth of approximately 94.38%[15] - The company reported a total liability of RMB 1,848,815,373.53, which is slightly higher than RMB 1,812,422,293.56 from the previous year, showing an increase of about 2.00%[17] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 33,387,660.96, down 92.65% year-over-year[5] - Cash flow from operating activities for the first three quarters of 2025 was CNY 33.39 million, a significant decrease compared to CNY 454.35 million in the same period of 2024[24] - Cash and cash equivalents at the end of the first three quarters of 2025 were approximately CNY 603.94 million, down from CNY 776.72 million at the end of the same period in 2024[24] - The company experienced a net cash outflow from investing activities of approximately CNY 54.22 million in the first three quarters of 2025, compared to a net outflow of CNY 50.72 million in the same period of 2024[24] Operational Challenges - The company faced significant challenges due to intensified market competition and reduced drug usage, leading to a substantial drop in sales prices and revenue[7] - The company incurred an administrative penalty of CNY 69,192,400 due to antitrust issues, impacting overall profitability[7] Strategic Initiatives - The company's net profit for the first nine months of 2025 is yet to be disclosed, but the financial statements indicate a focus on expanding product lines and market presence[18] - The company has successfully registered two products and received approval for one chemical raw material drug during the reporting period, enhancing its product portfolio[13] - The company plans to leverage its newly acquired drug production license to expand its market reach and enhance competitiveness in steroid products[12] - A loan of RMB 135 million has been approved for the company's subsidiary to support operational needs, with a term of three years[12] - The company appointed a new deputy general manager, indicating a strategic shift in management to support future growth initiatives[12] Cost Management - Total operating costs for the first three quarters of 2025 were approximately CNY 2.01 billion, a decrease of 11.7% compared to CNY 2.28 billion in the same period of 2024[19] - Research and development expenses for the first three quarters of 2025 were approximately CNY 90.35 million, an increase of 22.5% compared to CNY 135.81 million in the same period of 2024[20] - Sales expenses for the first three quarters of 2025 were approximately CNY 271.65 million, an increase of 36.3% compared to CNY 435.25 million in the same period of 2024[20] Inventory Management - The company has seen a decrease in inventory from RMB 651,915,382.71 to RMB 623,347,337.62, a reduction of approximately 4.39%[15]

关联交易管理制度 津药药业股份有限公司 关联交易管理制度 (2025年10月28日第九届董事会第二十一次会议审议通过) 第一章 总 则 第一条 为规范津药药业股份有限公司（以下简称"本 公司"、"公司"）及其控股子公司与各关联方的关联交易 行为，保证关联交易的公允性，维护公司、全体股东和债权 人，特别是中小投资者的合法利益，根据《中华人民共和国 公司法》《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司信息披露管理办法》《上海证券交易所股票上市 规则》（以下简称"《股票上市规则》"）、《上海证券交 易所上市公司自律监管指引第5号——交易与关联交易》等 法律、法规、规范性文件及《津药药业股份有限公司章程》 （以下简称"《公司章程》"）的有关规定，结合公司实际 情况，制定本制度。 第二条 公司与关联人进行交易时，应遵循以下基本原 则： （一）平等、自愿、等价、有偿的原则； （二）公平、公正、公开的原则； （三）在必需的关联交易中，关联股东和关联董事应当 执行《公司章程》规定的回避表决制度； 1 / 22 关联交易管理制度 （四）处理公司与关联人之间的关联交易，不得损害股 东特别是中小股东的合法权益。 ...